Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Fineline Cube May 28, 2026
Company Deals

Lantheus Holdings Receives $7 Billion Buyout Offer from Curium Pharma – Radiopharmaceutical Leader’s Alzheimer’s Portfolio Attracts Strategic Interest

Fineline Cube May 28, 2026
Company Deals

Viridian Therapeutics Secures Commercial Manufacturing Agreement with WuXi Biologics for Veligrotug – Anti-IGF-1R Antibody Advances Toward Thyroid Eye Disease Treatment

Fineline Cube May 28, 2026
Company Deals

Shanghai Pharma and Trinomab Partner to Commercialize Xintituo in Philippines – World’s First Recombinant Anti-Tetanus Toxin Monoclonal Antibody Expands Overseas

Fineline Cube May 28, 2026
Company Deals Drug

Shanghai Pharma Partners with BeOne Medicines on Imdelltra Distribution – Expanding Access to DLL3/CD3 Bispecific T-Cell Engager in China

Fineline Cube May 28, 2026
Policy / Regulatory

NMPA Issues Comprehensive Guidelines for Online Prescription Drug Retail, Mandating Human Pharmacist Review and AI Prescription Blocking

Fineline Cube May 26, 2026
Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Fineline Cube May 28, 2026
Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Fineline Cube May 28, 2026
Company Drug

Eli Lilly’s Mounjaro Approved by China’s NMPA for Long-Term Weight Management

Fineline Cube Jul 19, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical company in the US, has announced...

Hospital Policy / Regulatory R&D

China Issues Ethical Guidelines for Human Genome Editing, Prohibits Germline Editing

Fineline Cube Jul 19, 2024

China’s Ministry of Science and Technology (MOST) has issued the Ethical Guidelines for Human Genome...

Company Drug

China’s NMPA Suspends Daewoong Bio’s Cefodizime Over Inspection Refusal

Fineline Cube Jul 19, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Company Drug

Bain Capital-Backed Tenacia Wins NMPA Approval for Ganaxolone Oral Suspension for CDKL5 Deficiency

Fineline Cube Jul 19, 2024

Tenacia, a central nervous system (CNS) specialist company incubated by Bain Capital, has announced that...

Company Medical Device

MicroPort MedTech’s Vepack Filter Retriever Earns NMPA Marketing Approval

Fineline Cube Jul 19, 2024

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a prominent medical device company based in...

Company Medical Device

Venus Medtech’s VenusP-Valve Receives Marketing Approval in Venezuela, Expanding Global Reach

Fineline Cube Jul 19, 2024

Venus Medtech (Hangzhou) Inc., (HKG: 2500), a leading medical device company, has announced that it...

Company Drug

Anhui Anke Biotechnology Receives NMPA Clearance for Clinical Trial of mRNA Drug AFN0328 for HPV-Related Cancers

Fineline Cube Jul 19, 2024

Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009), a biopharmaceutical company based in China, has...

Company Medical Device

Shanghai Sanyou Medical’s Cervical Thoracic Internal Fixation System Earns NMPA Approval

Fineline Cube Jul 19, 2024

Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a leading medical device company based in China,...

Company Deals

Suzhou New District Hi-tech Industrial Co., Ltd and Subsidiaries to Establish Biopharmaceutical FOF with SND Group

Fineline Cube Jul 19, 2024

Suzhou New District Hi-tech Industrial Co., Ltd (SHA: 600736), a prominent company in China’s high-tech...

Company Deals

NeuShen Therapeutics and Livzon Pharma Strike Deal for Greater China Rights to NS-041

Fineline Cube Jul 19, 2024

NeuShen Therapeutics, a Sino-US biopharmaceutical company, has entered into a licensing agreement with Livzon Pharmaceutical...

Policy / Regulatory

NHSA Mandates Standardized Online Procurement for Injectable Drugs to Ensure Pricing Transparency

Fineline Cube Jul 18, 2024

The National Healthcare Security Administration (NHSA) has issued a directive to standardize the procurement process...

Company Drug

Consun Pharmaceutical Gets NMPA Go-Ahead for CKD Drug Clinical Trial

Fineline Cube Jul 18, 2024

Consun Pharmaceutical Group Ltd (HKG: 1681), a leading Chinese pharmaceutical company, has announced that it...

Company Drug

Shanghai Ruijin Hospital’s Hainan Subsidiary Adopts ANI Pharmaceuticals’ Veregen for HPV Treatment

Fineline Cube Jul 18, 2024

ANI Pharmaceuticals’ Veregen, a topical ointment derived from green tea extract (catechins), has been implemented...

Company Deals

Roche’s Genentech Terminates Relay Therapeutics Collaboration for SHP2 Inhibitor

Fineline Cube Jul 18, 2024

In a recent development, Roche Inc.’s subsidiary Genentech has given notice of termination for a...

Company

Johnson & Johnson Reports Robust Q2 2024 Earnings, Bolstered by Pharma and Medtech Growth

Fineline Cube Jul 18, 2024

Johnson & Johnson (NYSE: JNJ) has reported its financial results for the second quarter of...

Company Deals

Shanghai Escugen and Sidewinder Therapeutics Form Strategic Alliance for ADC Development

Fineline Cube Jul 18, 2024

Shanghai Escugen, a leading biopharmaceutical company specializing in antibody drug conjugates (ADCs), has announced a...

Company Drug

Junshi Biosciences’ Loqtorzi Inches Closer to Expanded Indication with NMPA Filing Acceptance

Fineline Cube Jul 18, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has taken a significant step forward...

Company Deals

SYNYI.AI Secures New Funding to Accelerate Digital Transformation in Healthcare

Fineline Cube Jul 18, 2024

Shanghai’s SYNYI.AI, a pioneering medical data mining and governance platform, has reportedly closed a new...

Company Deals

Boston Scientific Secures Silk Road Medical in a $1.16B Deal to Fortify Stroke Prevention Portfolio

Fineline Cube Jul 18, 2024

Boston Scientific Corporation (NYSE: BSX), a leading innovator in medical devices, has announced a definitive...

Company Deals

China Grand Pharmaceutical Expands with Mitsubishi Tanabe Pharma and Baiji Pharma Acquisitions

Fineline Cube Jul 18, 2024

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced the completion of...

Posts pagination

1 … 335 336 337 … 673

Recent updates

  • LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases
  • Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy
  • J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market
  • Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile
  • Dizal Pharmaceutical’s Zegfrovy Receives Priority Review for First-Line EGFR Exon20ins NSCLC – Phase III WU-KONG28 Data Shows Significant PFS Benefit Over Chemotherapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

LongBio Pharma Raises HKD 1.25 Billion in Hong Kong IPO – Clinical-Stage Biotech Advances Anti-IgE and Bifunctional Complement Inhibitors for Allergic and Autoimmune Diseases

Company Drug

Antengene Receives NMPA Approval for Phase III CLINCH-3 Trial of ATG-022 – CLDN18.2-Targeted ADC Advances in Gastric Cancer with Multi-Region Clinical Strategy

Company

J&J Appoints Han Ting as Shanghai-Based Immunology Head While Novartis China Announces Major Restructuring – Dual Leadership Shifts Signal Strategic Repositioning in China Market

Company Drug

Sino Biopharmaceutical Presents Promising Phase I Data for Kylo-0603 at EASL 2026 – THR-β Agonist Shows 28.5% LDL-C Reduction with Favorable Safety Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.